Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

AiRuiYi (fluzoparib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Jiangsu Hengrui Pharma

Drug class:

PARP inhibitor

Related drugs:

BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	fluzoparib Sensitive: B - Late Trials fluzoparib Sensitive : B	fluzoparib Sensitive: B - Late Trials fluzoparib Sensitive : B
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	fluzoparib Sensitive: B - Late Trials fluzoparib Sensitive : B	fluzoparib Sensitive: B - Late Trials fluzoparib Sensitive : B
BRCA mutation	HER2 Negative Breast Cancer	BRCA mutation	HER2 Negative Breast Cancer	rivoceranib + fluzoparib Sensitive: B - Late Trials rivoceranib + fluzoparib Sensitive : B	rivoceranib + fluzoparib Sensitive: B - Late Trials rivoceranib + fluzoparib Sensitive : B
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	fluzoparib Sensitive: C2 – Inclusion Criteria fluzoparib Sensitive : C2	fluzoparib Sensitive: C2 – Inclusion Criteria fluzoparib Sensitive : C2
BRCA2 mutation	Breast Cancer	BRCA2 mutation	Breast Cancer	fluzoparib Sensitive: C2 – Inclusion Criteria fluzoparib Sensitive : C2	fluzoparib Sensitive: C2 – Inclusion Criteria fluzoparib Sensitive : C2
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	rivoceranib + fluzoparib Sensitive: C2 – Inclusion Criteria rivoceranib + fluzoparib Sensitive : C2	rivoceranib + fluzoparib Sensitive: C2 – Inclusion Criteria rivoceranib + fluzoparib Sensitive : C2
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	rivoceranib + fluzoparib Sensitive: C2 – Inclusion Criteria rivoceranib + fluzoparib Sensitive : C2	rivoceranib + fluzoparib Sensitive: C2 – Inclusion Criteria rivoceranib + fluzoparib Sensitive : C2
BRCA1 mutation + BRCA2 mutation	Breast Cancer	BRCA1 mutation + BRCA2 mutation	Breast Cancer	fluzoparib Sensitive: C3 – Early Trials fluzoparib Sensitive : C3	fluzoparib Sensitive: C3 – Early Trials fluzoparib Sensitive : C3
BRCA1 mutation + BRCA2 mutation	Ovarian Cancer	BRCA1 mutation + BRCA2 mutation	Ovarian Cancer	fluzoparib Sensitive: C3 – Early Trials fluzoparib Sensitive : C3	fluzoparib Sensitive: C3 – Early Trials fluzoparib Sensitive : C3
LMO2 overexpression	T Cell Non-Hodgkin Lymphoma	LMO2 overexpression	T Cell Non-Hodgkin Lymphoma	fluzoparib Sensitive: C3 – Early Trials fluzoparib Sensitive : C3	fluzoparib Sensitive: C3 – Early Trials fluzoparib Sensitive : C3
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	rivoceranib + fluzoparib Sensitive: C3 – Early Trials rivoceranib + fluzoparib Sensitive : C3	rivoceranib + fluzoparib Sensitive: C3 – Early Trials rivoceranib + fluzoparib Sensitive : C3
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	rivoceranib + fluzoparib Sensitive: C3 – Early Trials rivoceranib + fluzoparib Sensitive : C3	rivoceranib + fluzoparib Sensitive: C3 – Early Trials rivoceranib + fluzoparib Sensitive : C3